Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare ...

AMGN beats fourth-quarter estimates for earnings and sales. FDA places clinical hold on a phase I study on its obesity ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

Erste Group upgraded shares of biotechnology firm Amgen (NASDAQ:AMGN) from Hold to Buy. The upgrade was primarily attributed to Amgen's financial performance, which includes a higher operating margin ...

Amgen (NASDAQ:AMGN – Get Free Report) is expected to be issuing its quarterly earnings data after the market closes on ...

Amgen (NASDAQ:AMGN – Free Report) had its price target decreased by Citigroup from $310.00 to $295.00 in a research report released on Tuesday morning,Benzinga reports. Citigroup currently has a ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

Amgen’s oncology portfolio achieved a number of successes too, with Kepivance being approved for oral mucositis as a side effect of chemotherapy in 2004, and monoclonal antibody Vectibix ...